In yesterday’s Wall Street session, MaxCyte Inc. (NASDAQ:MXCT) shares traded at $4.12, down -6.15% from the previous session.
As of this writing, 7 analysts cover MaxCyte Inc. (NASDAQ:MXCT). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $14.00 and a low of $9.00, we find $12.00. Given the previous closing price of $4.39, this indicates a potential upside of 173.35 percent. MXCT stock price is now -19.74% away from the 50-day moving average and -24.85% away from the 200-day moving average. The market capitalization of the company currently stands at $444.01M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
There are 0 analysts who have given it a hold rating, whereas 7 have given it a buy rating. Brokers who have rated the stock have averaged $11.81 as their price target over the next twelve months.
, while ‘Wedbush’ rates the stock as ‘Outperform’.
In other news, Ross Thomas M., EVP, Global Sales & Marketing sold 11,575 shares of the company’s stock on Feb 02. The stock was sold for $66,788 at an average price of $5.77. Upon completion of the transaction, the EVP, Global Sales & Marketing now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 02, President and CEO Doerfler Douglas sold 10,665 shares of the business’s stock. A total of $61,537 was realized by selling the stock at an average price of $5.77. This leaves the insider owning 333,197 shares of the company worth $1.37 million. Insiders disposed of 4,176,999 shares of company stock worth roughly $17.21 million over the past 1 year. A total of 1.24% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MXCT stock. A new stake in MaxCyte Inc. shares was purchased by AWM INVESTMENT COMPANY, INC. during the first quarter worth $1,648,000. STONEPINE CAPITAL MANAGEMENT, LLC invested $1,126,000 in shares of MXCT during the first quarter. In the first quarter, GAGNON SECURITIES LLC acquired a new stake in MaxCyte Inc. valued at approximately $142,000. PRINCIPAL FINANCIAL GROUP INC acquired a new stake in MXCT for approximately $93,000. JEFFERIES FINANCIAL GROUP INC. purchased a new stake in MXCT valued at around $75,000 in the second quarter. In total, there are 178 active investors with 85.40% ownership of the company’s stock.
Monday morning saw MaxCyte Inc. (NASDAQ: MXCT) opened at $4.2800. During the past 12 months, MaxCyte Inc. has had a low of $3.36 and a high of $7.76. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 15.00, and a quick ratio of 14.60. The fifty day moving average price for MXCT is $5.1335 and a two-hundred day moving average price translates $5.4820 for the stock.
The latest earnings results from MaxCyte Inc. (NASDAQ: MXCT) was released for Sep, 2022. According to the Medical Devices Company, earnings per share came in at -$0.06, beating analysts’ expectations of -$0.08 by 0.02. This compares to -$0.03 EPS in the same period last year. The net profit margin was -54.40% and return on equity was -8.80% for MXCT. The company reported revenue of $10.64 million for the quarter, compared to $10.14 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 4.97 percent. For the current quarter, analysts expect MXCT to generate $12.9M in revenue.
MaxCyte Inc.(MXCT) Company Profile
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
